Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy.
Martina PaolettiChiara BiniAndrea MarcellusiFrancesco Saverio MenniniPublished in: Clinical drug investigation (2024)
The analysis demonstrated that, compared with chemotherapy, pembrolizumab is more cost effective in Italy as a first-line treatment in patients with metastatic squamous or non-squamous NSCLC and, if compared with watchful waiting, as adjuvant treatment in patients with stage III melanoma. The present analysis suggested that pembrolizumab use could lead to important health benefits for patients while offsetting a portion of cancer care costs.
Keyphrases
- advanced non small cell lung cancer
- public health
- healthcare
- small cell lung cancer
- mental health
- end stage renal disease
- high grade
- early stage
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- health information
- prognostic factors
- risk assessment
- patient reported outcomes
- social media
- weight loss
- rectal cancer
- smoking cessation
- replacement therapy